India’s CDMO Sector Poised for Growth as Global Pharma Diversifies from China
The global pharmaceutical supply chain is undergoing a structural realignment as multinational companies seek to reduce their reliance on Chinese manufacturing. With increased regulatory scrutiny on Chinese giants like WuXi AppTec, India is rapidly emerging as the preferred alternative for global drugmakers.
The Strategic Shift Away from China
The transition toward Indian Contract Development and Manufacturing Organisations (CDMOs) is not a sudden reaction to recent geopolitical developments but a trend that began nearly two years ago. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, global pharmaceutical companies have already initiated conversations to diversify their manufacturing footprints.
The inclusion of certain entities in regulatory watchlists has further clarified the path for pharma companies to de-risk their supply chains. As global players move to ensure stability, Indian CDMOs are positioning themselves as reliable, high-quality partners capable of handling complex manufacturing needs.
Sai Life Sciences: Scaling Up for Global Demand
Leading this charge, Sai Life Sciences is aggressively expanding its capabilities to meet the shifting demand. The company has announced a significant capital expenditure (capex) plan, intending to invest between ₹1,100 crore and ₹1,300 crore in capacity expansion by FY27. This investment will be funded through a combination of internal accruals and debt, maintaining a healthy balance sheet.
A key indicator of this shifting landscape is the company's revenue mix. Over the last four years, the contribution from large global pharmaceutical companies has nearly doubled, rising from 28% to 49% of total revenue. This highlights a growing reliance on Indian manufacturers for both Research and Development (CRO) and manufacturing (CDMO) services.
From Clinical Trials to Commercial Manufacturing
A significant evolution is occurring in how global pharma utilizes Indian expertise. Previously, many companies relied on India primarily for clinical-stage supplies. However, there is a visible move toward using India for large-scale commercial manufacturing.
Sai Life Sciences has noted a substantial increase in late-stage development projects. The number of Phase III and pre-registration molecules has grown from six to eleven over the past year. This trend reflects growing confidence among global innovators that Indian facilities can meet the rigorous standards required for commercial-scale production and global distribution.
Long-term Growth vs. Immediate Timelines
While the opportunity is massive, industry experts caution that the benefits will materialize gradually. Because pharmaceutical manufacturing is heavily regulated, moving a product from one manufacturer to another requires extensive regulatory approvals and complex technology transfers.
Consequently, Sai Life Sciences has maintained its revenue growth guidance at a steady 15-20% CAGR. While the influx of new contracts may not impact quarterly results immediately, the structural shift promises a robust long-term growth trajectory for the entire Indian CDMO ecosystem.
Key Takeaways
- Diversification Trend: Global pharma is actively moving manufacturing away from China toward India to mitigate regulatory and supply chain risks.
- Capacity Expansion: Major Indian players like Sai Life Sciences are investing up to ₹1,300 crore to scale up production facilities by FY27.
- Commercial Shift: There is a fundamental transition in India's role, moving from providing clinical trial supplies to becoming a hub for large-scale commercial drug manufacturing.